Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: A randomized study

American Journal of Gastroenterology

Volumn 106, Issue 6, 2011, Pages 1081-1088

  Les, Ĩigo ^a,b   Doval, Eduardo ^b   García Martínez, Rita ^a,b   Planas, Mercè ^a   Cárdenas, Guillermo ^a   Gómez, Pilar ^a   Flavi, Montse ^a   Jacas, Carlos ^a,c   Mínguez, Beatriz ^a,c   Vergara, Mercedes ^c,d   Soriano, Germán ^c,e   Vila, Carmen ^f   Esteban, Rafael ^a,b,c   Córdoba, Juan ^a,b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Servei de Aparell Digestiu   (Spain)

^e Hospital Sant Pau   (Spain)

^f HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRANCHED CHAIN AMINO ACID; CREATININE; MALTODEXTRIN; NEOMYCIN; PROTEIN; SERUM ALBUMIN; SODIUM;

ADULT; ARM CIRCUMFERENCE; ARM MUSCLE; ARTICLE; COGNITION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE MASS; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; TERTIARY HEALTH CARE;

AGED; AMINO ACIDS, BRANCHED-CHAIN; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; DIET, PROTEIN-RESTRICTED; DIETARY SUPPLEMENTS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPATIC ENCEPHALOPATHY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYSACCHARIDES; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79958002114     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.9     Document Type: Article

References (36)

1. Bustamante J, Rimola A, Ventura PJ et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-5. (Pubitemid 29248991)
2. Marchesini G, Bianchi G, Amodio P et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 170-8. (Pubitemid 32061881)
3. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001; 96: 1968-76. (Pubitemid 32660887)
4. Kondrup J, Muller MJ. Energy and protein requirements of patients with chronic liver disease. J Hepatol 1997; 27: 239-47. (Pubitemid 27357083)
5. Soulsby CT, Morgan MY. Dietary management of hepatic encephalopathy in cirrhotic patients: survey of current practice in United Kingdom. BMJ 1999; 318: 1391. (Pubitemid 29237832)
6. Plauth M, Merli M, Kondrup J. Management of hepatic encephalopathy. N Engl J Med 1997; 337: 1921-2.
7. Cordoba J, Lopez-Hellin J, Planas M et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41: 38-43. (Pubitemid 39005150)
8. Mullen KD, Weber FL Jr. Role of nutrition in hepatic encephalopathy. Semin Liver Dis 1991; 11: 292-304.
9. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971; 2: 75-80.
10. Butterworth RF. Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems. Curr Opin Neurol 2000; 13: 721-7. (Pubitemid 32002658)
11. Egberts EH, Schomerus H, Hamster W et al. Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double-blind placebo-controlled crossover study. Gastroenterology 1985; 88: 887-95. (Pubitemid 15105878)
12. Plauth M, Egberts EH, Hamster W et al. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A doubleblind placebo-controlled crossover study. J Hepatol 1993; 17: 308-14. (Pubitemid 23134926)
13. Marchesini G, Dioguardi FS, Bianchi GP et al. Long-term oral branchedchain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990; 11: 92-101. (Pubitemid 20250834)
14. Holecek M. Th ree targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition 2010; 26: 482-90.
15. Muto Y, Sato S, Watanabe A et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705-13. (Pubitemid 40984733)
16. Olde Damink SW, Jalan R, Redhead DN et al. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36: 1163-71. (Pubitemid 35253432)
17. Marchesini G, Bianchi G, Merli M et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124: 1792-801. (Pubitemid 36666776)
18. Als-Nielsen B, Koretz RL, Kjaergard LL et al. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003; (2): CD001939.
19. Charlton M. Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis? N at Clin Pract Gastroenterol Hepatol 2 006; 3: 7 2-3.
20. Planas M, P é rez-Portabella C, Mart í nez C. Valoraci ó n del estado nutricional en el adulto y en el ni ñ o. In: Gil Hern á ndez G (ed). Tratado de Nutrici ó n, 2nd edn, Editorial M é dica Panamericana: Madrid, Spain, 2010, p 67.
21. Kamath PS. The need for better clinical trials. Hepatology 2008; 48: 1-3. (Pubitemid 351975522)
22. Alonso J, Prieto L, Anto JM. The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc) 1995; 104: 771-6.
23. Ferrer M, Cordoba J, Garin O et al. Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl 2006; 12: 95-104.
24. Guevara M, Baccaro ME, Torre A et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 2009; 104: 1382-9.
25. Riggio O, Angeloni S, Salvatori FM et al. Incidence, natural history, and risk factors of hepatic encephalopathy aft er transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent graft s. Am J Gastroenterol 2008; 103: 2738-46.
26. McCrea M, Cordoba J, Vessey G et al. Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Arch Neurol 1996; 53: 758-63. (Pubitemid 26266921)
27. Ichida T, Shibasaki K, Muto Y et al. Clinical study of an enteral branchedchain amino acid solution in decompensated liver cirrhosis with hepatic encephalopathy. Nutrition 1995; 11: 238-44.
28. Marchesini G, Zoli M, Dondi C et al. Anticatabolic effect of branched-chain amino acid-enriched solutions in patients with liver cirrhosis. Hepatology 1982; 2: 420-5. (Pubitemid 12046836)
29. Bianchi G, Marzocchi R, Agostini F et al. Update on branched-chain amino acid supplementation in liver diseases. Curr Opin Gastroenterol 2005; 21: 197-200. (Pubitemid 40316203)
30. Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology 1996; 23: 1041-6.
31. Angeli P, Wong F, Watson H et al. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006; 44: 1535-42. (Pubitemid 44953659)
32. Cordoba J, Garcia-Martinez R, Simon-Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence. Metab Brain Dis 2010; 25: 73-80.
33. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28: 81-95. (Pubitemid 351326535)
34. Sotil EU, Gottstein J, Ayala E et al. Impact of preoperative overt hepatic encephalopathy on neurocognitive function aft er liver transplantation. Liver Transpl 2009; 15: 184-92.
35. Bajaj JS, Schubert CM, Heuman DM et al. Persistence of cognitive impairment aft er resolution of overt hepatic encephalopathy. Gastroenterology 2010; 138: 2332-40.
36. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Th er 2007; 25 (Suppl 1): 3-9. (Pubitemid 46148239)